EDWARDS LIFESCIENCES CORPORATION (EW): what the price assumes

In the published model solve dated 2026-Q2, anchored at $90.21, EDWARDS LIFESCIENCES CORPORATION (EW) is priced for today's economics sustained for ~5.8 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/EW

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=15)

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Three quarters of revenue comes from one procedure, threading a replacement aortic valve up an artery instead of opening the chest, with the newer mitral and tricuspid line at "9%, 7%, and 4% of our net sales in 2025, 2024, and 2023, respectively" and surgical tissue valves at 17% of 2025 sales.
• Reported operating profit went backwards in 2025 even as sales rose $628.1 million, because intellectual property litigation expenses, settlements, and external legal costs jumped to $325.4 million from $40.4 million a year earlier.
• The next decision point is regulatory rather than commercial: Medicare's national coverage rules for the aortic valve procedure are under reconsideration, with a final decision memo expected in September 2026.

Bull Case

Most medical device companies are valued on how well they defend an installed base. Structural heart does not work that way. A replacement heart valve goes in once, into a patient who would otherwise face open-chest surgery or nothing at all, so the growth question is not how much share Edwards takes from a rival. It is how many people get diagnosed and referred in the first place. The 10-K describes the mechanic without drama: "The SAPIEN valves are delivered while the heart is still beating." Most patients skip general anesthesia and go home inside two days. That is not a product feature. It is the reason the treatable population keeps getting larger.

The moat here is clinical evidence, which is slow to build and impossible to copy quickly. The company reports that "In 2024, EARLY TAVR trial data demonstrated the superiority of early TAVR intervention in severe asymptomatic aortic stenosis patients with the SAPIEN 3 platform versus clinical surveillance." Read that as a business fact rather than a medical one. Patients without symptoms are the largest untreated group in aortic stenosis, and until a randomized trial says treat them, the guideline says watch and wait. Edwards runs the trial that changes the guideline that creates the patient. Its named rivals are not small: the 10-K states "In TAVR, our primary competitors include Medtronic plc (Medtronic) and Abbott Laboratories (Abbott)." Both can build a valve. Neither can retroactively enroll a decade of patients.

The compounding lives in the second line. Mitral and tricuspid therapies grew 51.9% in the first quarter of 2026 to $175.1 million on the strength of the PASCAL repair system and the EVOQUE tricuspid replacement valve, the latter of which the company describes as the world's first transcatheter tricuspid replacement therapy to win regulatory approval. Surgical valves, which look like the sleepy remainder of the portfolio, are doing quieter work: the 10-K reports RESILIA tissue with "published clinical data showing over 99% freedom from structural valve deterioration through eight years". Durability is the entire argument for implanting a valve in a younger patient, and a younger patient is a larger market.

Underneath, the operating economics are strong and the financing picture is boring in the best way. In the first quarter of 2026 the company reported operating income, net of $477.6 million on net sales of $1,648.6 million. Interest income of $168.8 million in 2025 was many times the $20.4 million of interest expense it paid. And the diluted share count has fallen in each of the three most recently reported years, from 609.4 million to 599.3 million to 585.8 million, supported by repurchase authorizations of 1.5 billion dollars approved in August 2024 and a further 1.5 billion dollars in September 2025. A falling share count is the one form of capital return that cannot be dressed up.

The bear will point out that the growth is not singular, and that is fair. ISRG grew revenue 21.4% while earning a 30.5% operating margin; BSX grew 17.4% at an 18.4% margin; the larger and slower MDT grew 8.4% and SYK 8.8%. Edwards sits in the fast half of that group without either giant's scale. That is precisely the profile that rewards a company doing one thing extremely well, and the one thing here happens to be the valve most studied in the world.

Bear Case

Hospitals have a fixed number of catheterization labs and a fixed number of teams trained to work in them, and that ceiling is the thing nobody in this business mentions on a good day. Edwards mentions it, in its own risk factors: "We have in the past and are continuing to experience constrained procedure volumes and sales for our products because more products, including Edwards' own products, are competing for the same facilities and staffing within hospitals." Read the middle of that sentence again. Growth in mitral and tricuspid procedures competes with the aortic franchise for the same room and the same staff. Adding products does not add capacity, and a portfolio that broadens faster than hospital throughput expands is competing with itself.

That matters because of what the price has already booked. The market is paying for operating profit to compound at the top of the rate this company can fund out of its own earnings, and to hold that pace for about five years before slowing. Of companies that have grown that quickly, only around 29% kept it going that long. The demonstrated record is less obliging than the assumption: reported operating profit for 2025 came in below 2024 even though sales rose $628.1 million. If the compounding runs short of what is booked, the asset-value and earnings-power methods are where the price would land, and both sit at roughly a quarter of today's level.

The legal line is not noise, either. Intellectual property litigation expenses, settlements, and external legal costs ran $325.4 million in 2025, $40.4 million in 2024 and $203.5 million in 2023. That is not a one-off in any useful sense. It is a lumpy recurring expense of operating in a field where every design is patented by somebody, and the pattern shows up again this year: Cardiovalve, Ltd. and MTH IP, L.P. sued on January 14, 2026 alleging the PASCAL products infringe their patent, and on February 16, 2026 the Valtech shareholder representative filed in Delaware seeking accelerated milestone payments from a prior acquisition. The 2023 settlement with Medtronic bought a global covenant not to sue, running from April 2023 through April 2038, for a lump sum of $300.0 million plus annual royalties tied to net sales of certain Edwards products. A slice of every future valve sold is already committed to a competitor.

Then there is what the pipeline costs when it does not work. Edwards funds small valve developers through convertible notes and purchase options, then exercises when the data cooperates. When it does not, the money is gone. A $146.9 million impairment landed in 2025 on a promissory note investment and a decision not to exercise an acquisition option, and another $123.6 million followed in the first quarter of 2026 when the carrying amounts of further investments were judged unrecoverable. Set against a single year of operating profit, two write-downs of that size inside five quarters are not rounding.

None of this is a solvency argument, and pretending otherwise would be dishonest. Cash and equivalents stood near 2.9 billion dollars at June 30, 2026 against total borrowings of roughly 600 million dollars, the company collects far more interest than it pays, and the share count keeps shrinking. The bear case is narrower than solvency and harder to dismiss for it. The price needs the compounding to keep running for years, in a business whose own filings say the rooms are already full.

Valuation

Start with what the price has to believe. The market is paying for operating profit to grow at the top of the rate this company can fund from its own earnings, and then to hold that pace for about five years before fading. The rate itself is not outlandish; it is close to what the recent record shows. The stretch is the duration. Among companies that have grown that fast, only around 29% sustained it that long, which is what makes the assumption elevated rather than merely optimistic.

The methods used to triangulate a value disagree sharply here, and the shape of the disagreement is the useful part. Asset-value methods and earnings-power methods both land at roughly a quarter of the current quote. The peer-multiple approaches land nearer half. Only the forward-growth methods reach the price at all. That pattern has a name in plain English: it is a durability premium, a bet that the compounding lasts, and the static frames cannot price it because they are not built to.

One method makes the gap concrete. The earnings-power approach takes a normalized operating profit averaged across five years, taxes it, capitalizes it at the return an investor should require, and credits no growth whatsoever. It lands near a quarter of today's quote. The distance is not a flaw in the method. It is the whole value of the growth, isolated and sitting there where it can be looked at.

The reported inputs are worth stating plainly, because two different pictures live inside them. For the year ended December 31, 2025 the company reported net sales of $6,067.6 million and operating income of $1,264.2 million, a figure held down by a legal line that reached $325.4 million. For the three months ended March 31, 2026 it reported operating income, net of $477.6 million on net sales of $1,648.6 million. Same business, and the quarterly figure runs several points richer against sales. Which of those the price is compounding from is the live question, and it is not a rhetorical one.

Against the comparable set the multiple sits where the growth would suggest. The peer-multiple approach blends a sector reference with the company's own trailing earnings multiple, and even that blend lands under the price; the sales-based version applies a sector multiple to revenue of $6.30 billion and lands further under still. ISRG, the closest thing here to a growth-and-margin peer, earns a 30.5% operating margin on revenue of 10.58 billion dollars growing 21.4%. BSX runs an 18.4% margin growing 17.4%. Edwards' economics sit inside that band rather than above it, which means the premium is not being paid for superior current economics.

Borrowings are small enough that the company earns considerably more in interest than it pays, and the diluted share count has fallen in each of the three most recently reported years, from 609.4 million to 585.8 million. That takes financing risk out of the downside and leaves the question where it started, which is time: how many years of compounding the price has already booked, and how many the business goes on to deliver.

Catalysts

Second quarter results landed on July 23, 2026. Sales grew 13.6% to $1.74 billion, with the aortic valve line up 11.3% to $1.26 billion, mitral and tricuspid up 47.3% to $195.9 million, and surgical up 6.5% to $284 million. Reported earnings were $0.42 a share for the quarter, and management noted that growth benefited from a competitor's exit in the year-ago period while average selling prices held stable globally. Full-year sales growth guidance moved up to a range of 10% to 11% from 9% to 11%, with 2026 sales now expected between $6.6 billion and $6.9 billion and third-quarter sales projected between $1.63 billion and $1.71 billion.

The next two quarters are unusually event-dense, and most of the events are regulatory rather than commercial. Medicare's national coverage determination for the aortic valve procedure is under reconsideration, with a final decision memo expected in September 2026. In the fourth quarter the company expects United States approval of the PASCAL system for tricuspid patients and approval of the next-generation PASCAL device in both the United States and Europe, alongside presentation of the PROGRESS trial in moderate aortic stenosis and the CLASP IITR results. PROGRESS is the one worth watching. Moderate disease is a far larger population than severe disease, and a positive read would lift the ceiling on the franchise rather than on any single product.

Two smaller moves this year show where the pipeline money goes. On February 6, 2026 Edwards exercised an option and acquired Autus Valve Technologies, a clinical-stage developer of a pulmonary valve for children with congenital valve disease, for total consideration of $128.9 million with up to $132.5 million more tied to regulatory approval and sales milestones. In January it put $45.0 million into a convertible promissory note issued by JenaValve Technology under a merger agreement signed in July 2024, and in the same quarter recognized a $123.6 million impairment on other investments whose carrying amounts were judged unrecoverable. Fund the optionality early through notes and options; write it down without ceremony when the data does not come.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• BSX (BOSTON SCIENTIFIC CORP)
• FY2025 10-K: …technological changes in the medical devices industry or low-cost competitive offerings, which could have an adverse effect on our business, financial condition or results of operations. The medical device markets in which we participate are highly competitive. We encounter significant competition across our product…
• FY2025 10-K: …devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.…
• PEN (Penumbra, Inc)
• FY2025 10-K: …or regulatory changes to reimbursement policies could potentially limit the amount which healthcare providers may be willing to pay for medical devices. Competition The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market…
• FY2025 10-K: …condition and cash flows. We may not be able to achieve or maintain satisfactory pricing and margins for our products. Manufacturers of medical devices have a history of price competition, and we can give no assurance that we will be able to achieve satisfactory prices for our products or maintain prices at the…
• ISRG (Intuitive Surgical, Inc.)
• FY2025 10-K: …robotics and become competitors. Additionally, we expect increasing competition within China for robotic-assisted systems. Our revenues may be reduced due to pricing pressure if our competitors develop and market products that are more effective or less expensive than our products. In addition, research efforts…
• FY2025 10-K: …research organizations may conduct research, seek patent protection, and establish collaborative arrangements for discovery, research, and marketing of products similar to ours. These companies and institutions compete with us in recruiting and retaining qualified scientific and management personnel, as well as in…
• GMED (GLOBUS MEDICAL, INC.)
• FY2025 10-K: …sales, operating results, and growth may be negatively affected. Our industry is intensely competitive, subject to rapid change and highly sensitive to the introduction of new products or other market activities of industry participants. We believe that our significant competitors are Medtronic, DePuy Synthes,…
• FY2025 10-K: …GLOBUS MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) conclusions reached after considering relevant factors such as economic similarity, customer base, regulatory environment, production processes, nature of services and products provided, and our comprehensive approach to…
• MDT (Medtronic plc)
• FY2025 10-K: …operating profit in the budget and forecasting process and to monitor budget and forecast variances versus actual when assessing segment performance and allocating capital resources to each segment. The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be…
• FY2025 10-K: …services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. The…
• SYK (STRYKER CORP)
• FY2025 10-K: …products restricts competitors from duplicating these unique designs and features. We seek to obtain patent protection on our products whenever appropriate for protecting our competitive advantage. On December 31, 2025 we owned approximately 5,600 United States patents and approximately 9,000 patents in other…
• FY2025 10-K: …sales by 0.5% . Excluding the 0.7% impact of acquisitions and divestitures, net sales in constant currency increased by 8.7% from increased unit volume. The unit volume increase was due to higher shipments across all Orthopaedics businesses. Gross Pro fit Gross profit was $ 16,065 , $ 14,440 and $ 13,058 in 2025 ,…
• TFX (TELEFLEX INCORPORATED)
• FY2025 10-K: …financial information is available. The chief operating decision maker utilizes segment operating profit to evaluate operating expenses through a comparison of budget to actual results as well as an analysis of operating expenses as a percentage of revenue. We do not evaluate our operating segments using discrete…
• FY2025 10-K: …predominance of government-sponsored healthcare systems around the world, most of our customer relationships outside of the U.S. are with government entities and are therefore subject to such anti-bribery laws. Our policies mandate compliance with these anti-bribery laws. We operate in many parts of the world that…
• MMSI (MERIT MEDICAL SYSTEMS INC)
• FY2025 10-K: …of cardiology, radiology, oncology, critical care and endoscopy. This marketplace is characterized by rapid technological advancement, industry and customer consolidation, customer demands for price reductions, regulatory reform, and evolving patient needs. We compete with companies of varying sizes. Many of our…
• FY2025 10-K: …("Teleflex"), Cook Medical Incorporated ("Cook Medical"), Medtronic plc ("Medtronic"), Boston Scientific Corporation ("Boston Scientific"), and Becton, Dickinson and Company ("BD"). Our primary competitors in our cardiac intervention market are BD, Teleflex, Medtronic, Abbott Laboratories, Terumo Corporation, Edwards…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.